{"slideshow_credits": null, "snippet": "The entrepreneur, who has been criticized for price gouging on drugs, faces securities fraud charges related to his work at MSMB Capital Management and Retrophin.", "abstract": "Federal Bureau of Investigation arrests Turing Pharmaceuticals head Martin Shkreli, who has been vilified for drug price-gouging, on securities fraud and wire fraud charges relating to his work at hedge fund MSMB Capital Management and biopharmaceutical company Retrophin; critics assert arrest is comeuppance for brash chief executive officer.", "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Julie", "role": "reported", "lastname": "CRESWELL", "rank": 1, "organization": ""}, {"firstname": "Stephanie", "role": "reported", "lastname": "CLIFFORD", "rank": 2, "organization": ""}, {"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 3, "organization": ""}], "original": "By JULIE CRESWELL, STEPHANIE CLIFFORD and ANDREW POLLACK", "contributor": "Matthew Goldstein and David Chen contributed reporting."}, "web_url": "http://www.nytimes.com/2015/12/18/business/shkreli-fraud-charges.html", "lead_paragraph": "The entrepreneur, who has been criticized for price gouging on drugs, faces securities fraud charges related to his work at MSMB Capital Management and Retrophin.", "headline": {"main": "Drug C.E.O. Martin Shkreli Arrested on Fraud Charges", "print_headline": "F.B.I. Arrests C.E.O. Vilified for Drug Costs"}, "_id": "5672b86f38f0d82eed76c633", "word_count": "1356", "multimedia": [{"height": 126, "url": "images/2015/12/18/business/18shkreli-web4/18shkreli-web4-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2015/12/18/business/18shkreli-web4/18shkreli-web4-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 402, "url": "images/2015/12/18/business/18shkreli-web4/18shkreli-web4-articleLarge.jpg", "legacy": {"xlarge": "images/2015/12/18/business/18shkreli-web4/18shkreli-web4-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "402"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2015/12/18/business/18shkreli-web4/18shkreli-web4-thumbStandard.jpg", "legacy": {"thumbnail": "images/2015/12/18/business/18shkreli-web4/18shkreli-web4-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2015-12-18T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "persons", "value": "Shkreli, Martin (1983- )", "is_major": "Y", "rank": "1"}, {"name": "organizations", "value": "MSMB Capital Management LLC", "is_major": "Y", "rank": "2"}, {"name": "organizations", "value": "Turing Pharmaceuticals AG", "is_major": "Y", "rank": "3"}, {"name": "organizations", "value": "Retrophin Inc", "is_major": "Y", "rank": "4"}, {"name": "subject", "value": "Securities and Commodities Violations", "is_major": "Y", "rank": "5"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "6"}, {"name": "organizations", "value": "Federal Bureau of Investigation", "is_major": "Y", "rank": "7"}, {"name": "subject", "value": "Hedge Funds", "is_major": "N", "rank": "8"}], "blog": [], "subsection_name": null, "type_of_material": "News"}